The tumor microenvironment in leukemia: molecular pathways of immune evasion - PubMed
2 months ago
- #immunotherapy
- #immune evasion
- #leukemia
- The tumor microenvironment (TME) in leukemia plays a critical role in immune evasion and therapeutic resistance.
- Key mechanisms of immune evasion include T-cell exhaustion, regulatory T cells (Tregs), and antigen-presentation deficits.
- Leukemia remains a significant global burden with approximately 460,000 new cases and 320,000 deaths in 2021.
- The bone-marrow niche and B-cell dysregulation in chronic lymphocytic leukemia (CLL) contribute to immune evasion.
- Immunotherapy agents like magrolimab combined with azacitidine show promise with over 80% objective response rates in AML trials.
- Challenges such as on-target anemia persist in immunotherapy treatments.
- E-selectin inhibition (uproleselan) and preclinical metabolic profiling are being explored for innovative treatments.
- Multifaceted immunotherapeutic approaches are needed to address the complex interactions within the TME.